This company listing is no longer active
Initiator Pharma Past Earnings Performance
Past criteria checks 0/6
Key information
-21.6%
Earnings growth rate
23.8%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -177.3% |
| Net Margin | n/a |
| Next Earnings Update | 26 Aug 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Initiator Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 0 | -34 | 2 | 0 |
| 31 Dec 21 | 0 | -21 | 1 | 0 |
| 30 Sep 21 | 0 | -16 | 1 | 0 |
| 30 Jun 21 | 0 | -10 | 1 | 0 |
| 31 Mar 21 | 0 | -8 | 1 | 0 |
| 31 Dec 20 | 0 | -9 | 1 | 0 |
| 30 Sep 20 | 0 | -10 | 1 | 0 |
| 30 Jun 20 | 0 | -9 | 1 | 0 |
| 31 Mar 20 | 0 | -9 | 1 | 0 |
| 31 Dec 19 | 0 | -8 | 1 | 0 |
| 30 Sep 19 | 0 | -7 | 1 | 0 |
| 30 Jun 19 | 0 | -9 | 1 | 0 |
| 31 Mar 19 | 0 | -8 | 1 | 0 |
| 31 Dec 18 | 0 | -10 | 1 | 0 |
| 30 Sep 18 | 0 | -13 | 1 | 0 |
| 30 Jun 18 | 0 | -11 | 1 | 0 |
| 31 Mar 18 | 0 | -10 | 1 | 0 |
| 31 Dec 17 | 0 | -9 | 1 | 0 |
| 30 Sep 17 | 0 | -7 | 1 | 0 |
Quality Earnings: INIT BTA is currently unprofitable.
Growing Profit Margin: INIT BTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INIT BTA is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.
Accelerating Growth: Unable to compare INIT BTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INIT BTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.6%).
Return on Equity
High ROE: INIT BTA has a negative Return on Equity (-177.26%), as it is currently unprofitable.